M&A / Deals Ipsen charts $1.75bn course for Kartos acquisition PharmaphorumIpsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.HematologyRead full story pharminent June 29, 2026 (Last updated: June 30, 2026) Pharmaphorum Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class. Hematology Read full story Post navigation Previous: Lilly’s Jaypirca receives CHMP positive opinion for CLL in EuropeNext: Viridian wins FDA approval for Lumvoa for thyroid eye disease Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026